Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose‐Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo

• DOI: 10.1155/2016/9785890
• Publication Date: 2016-04-18T21:03:21Z
• Authors: Krzysztof Marycz; Krzysztof A. Toma...; Katarzyna Kornicka; Brandon Michael H...; Sebastian Wroński; Jacek Tarasiuk; Monika Maredziak
• Keywords: 0301 basic medicine; Adipogenesis; Cell Survival; Osteocalcin; Bone Morphogenetic Protein 2; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Mesenchymal Stem Cells; Bone and Bones; Metformin; Immunophenotyping; 3. Good health; Mice, Inbred C57BL; Mice; Oxidative Stress; 03 medical and health sciences; Adipose Tissue; Bone Density; Osteogenesis; Animals; Osteopontin; Cells, Cultured; Cellular Senescence; Research Article

Due to its pleiotropic effects, the commonly used drug metformin has gained renewed interest among medical researchers. While metformin is mainly used for the treatment of diabetes, recent studies suggest that it may have further application in anticancer and antiaging therapies. In this study, we investigated the proliferative potential, accumulation of oxidative stress factors, and osteogenic and adipogenic differentiation potential of mouse adipose‐derived stem cells (MuASCs) isolated from mice treated with metformin for 8 weeks. Moreover, we investigated the influence of metformin supplementation on mice bone density and bone element composition. The ASCs isolated from mice who were treated with metformin for 8 weeks showed highest proliferative potential, generated a robust net of cytoskeletal projections, had reduced expression of markers associated with cellular senescence, and decreased amount of reactive oxygen species in comparison to control group. Furthermore, we demonstrated that these cells possessed greatest osteogenic differentiation potential, while their adipogenic differentiation ability was reduced. We also demonstrated that metformin supplementation increases bone density in vivo. Our result stands as a valuable source of data regarding the in vivo influence of metformin on ASCs and bone density and supports a role for metformin in regenerative medicine.